Background: Pityriasis Rosea (PR) is an acute inflammatory and self-limiting skin disorder, sometimes with troublesome symptoms. To date, there are few treatments available for this disorder.
Aim: Compare the traditional treatment with erythromycin to a newly introduced antiviral treatment acyclovir for PR.